

Communication

Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of “False-Positive” Cases

Manabu Natsumeda ^{1,*}, Hironaka Igarashi ^{2,*}, Ramil Gabdulkaev ³, Haruhiko Takahashi ¹,
Kunio Motohashi ¹, Ryosuke Ogura ¹, Jun Watanabe ¹, Yoshihiro Tsukamoto ¹, Kouichirou Okamoto ⁴,
Akiyoshi Kakita ³, Tsutomu Nakada ² and Yukihiko Fujii ¹

- ¹ Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8122, Japan; haruhiko.takahashi@icloud.com (H.T.); kmoto@bri.niigata-u.ac.jp (K.M.); oguryou@bri.niigata-u.ac.jp (R.O.); watanabejun1003@yahoo.co.jp (J.W.); yoshi.tsukamoto@me.com (Y.T.); yfujii@bri.niigata-u.ac.jp (Y.F.)
- ² Center for Integrated Brain Sciences, Brain Research Institute, Niigata University, Niigata 951-8585, Japan; tnakada@bri.niigata-u.ac.jp
- ³ Department of Pathology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan; ram.gab258852@gmail.com (R.G.); kakita@bri.niigata-u.ac.jp (A.K.)
- ⁴ Department of Translational Research, Brain Research Institute, Niigata University, Niigata 951-8585, Japan; oko-okamoto@bri.niigata-u.ac.jp
- * Correspondence: natsumeda@bri.niigata-u.ac.jp (M.N.); higara@bri.niigata-u.ac.jp (H.I.)



Citation: Natsumeda, M.; Igarashi, H.; Gabdulkaev, R.; Takahashi, H.; Motohashi, K.; Ogura, R.; Watanabe, J.; Tsukamoto, Y.; Okamoto, K.; Kakita, A.; et al. Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of “False-Positive” Cases. *Diagnostics* **2021**, *11*, 2129. <https://doi.org/10.3390/diagnostics11112129>

Academic Editor: Silvia Morbelli

Received: 26 October 2021

Accepted: 15 November 2021

Published: 16 November 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: We have previously published a study on the reliable detection of 2-hydroxyglutarate (2HG) in lower-grade gliomas by magnetic resonance spectroscopy (MRS). In this short article, we re-evaluated five glioma cases originally assessed as isocitrate dehydrogenase (IDH) wildtype, which showed a high accumulation of 2HG, and were thought to be false-positives. A new primer was used for the detection of *IDH2* mutation by Sanger sequencing. Adequate tissue for DNA analysis was available in 4 out of 5 cases. We found rare *IDH2* mutations in two cases, with *IDH2* R172W mutation in one case and *IDH2* R172K mutation in another case. Both cases had very small mutant peaks, suggesting that the tumor volume was low in the tumor samples. Thus, the specificity of MRS for detecting IDH1/2 mutations was higher (81.3%) than that originally reported (72.2%). The detection of 2HG by MRS can aid in the diagnosis of rare, non-IDH1-R132H *IDH1* and *IDH2* mutations in gliomas.

Keywords: 2-hydroxyglutarate; glioma; magnetic resonance spectroscopy; rare IDH mutations; false-positive

1. Introduction

Isocitrate dehydrogenase (IDH)-mutant gliomas produce the oncometabolite 2-hydroxyglutarate (2HG). We previously reported on the reliable detection of 2HG by 3.0-tesla magnetic resonance spectroscopy (MRS) in a cohort of 52 lower-grade glioma patients (WHO grades 2 and 3) [1]. A cutoff of 1.489 mM for 2HG yielded 100% sensitivity and a 72.2% specificity for the detection of *IDH1* or *IDH2* mutations was reported. A high level of 2HG was detected in 5 of 27 (18.5%) gliomas that were determined to be IDH-wildtype. These were thought to be false-positive results or a failure to detect rare *IDH1* or *IDH2* mutations by DNA sequencing [1]. The unambiguous detection of 2HG (chemical shift 2.25 ppm) by MRS is difficult because of a spectral overlap with glutamate (Glu; 2.43 ppm), glutamine (Gln; 2.34 ppm), and gamma-aminobutyric acid (GABA; 2.28 ppm). Recently, the tumor recurred in one of the five patients, and the patient underwent a second surgery. An analysis of *IDH1/2* mutations using Sanger sequencing revealed an *IDH2* mutation. In the current study, we re-evaluated *IDH1* and *IDH2* status in the remaining “false-positive”

cases with available tissue. We found that the 2HG detection by MRS was useful in the selection of glioma cases with rare *IDH1* and *IDH2* mutations.

2. Materials and Methods

MRI/1H-MRS was performed using a 3.0-tesla system (Signa LX, General Electric, Waukesha, WI, USA) as previously reported [1], in accordance with the human research guidelines of the Internal Review Board of Niigata University (Approval #2017-0163) after obtaining written consent from all participants. Proton density images (Fast Spin Echo; TR/TE = 5000/40; FOV: 20 × 20 mm; matrix: 256 × 256; slice thickness: 5 mm; interslice gap: 2.5 mm) were captured. The slice with the largest depiction of the tumor on proton density images was selected for SVMRS. A point-resolved spectroscopic sequence (PRESS) with a chemical-shift-selective water suppression was used with the following parameters: TR: 1.5 s; TE: 30 ms; data point 512; spectral width 1000 Hz; number of acquisitions: 128–196; volume of interest (VOI): 12–20 × 12–20 × 12–20 mm). The volume of interest (VOI) was designed to minimize the suspected areas of necrosis and hemorrhage. A spectral analysis was performed using LCMoDel version 6.3 (Stephen Provencher, Oakville, ON, Canada) [2]. This software automatically adjusts the phase and chemical shift of the spectra, estimates the baseline, and performs eddy current corrections. Relative metabolite concentrations and their uncertainties were estimated by fitting the spectrum to a basis set of spectra acquired from individual metabolites in-solution. The basis set was provided by Dr. Steven Provencher [2] and was calibrated with an MRS phantom solution (18-cm-diameter MRS HDsphere, model 2152220; General Electric) using our MR system. Nineteen metabolites were included in the LCMoDel basis set, including alanine, aspartate, creatine (Cr), phosphocreatine (PCr), GABA, glucose, Gln, Glu, glycerophosphocholine (GPC), phosphocholine (PC), glutathione (GSH), 2HG, myo-inositol (Ins), lactate, N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), scyllo-inositol, taurine, and guanine. Total NAA (tNAA: the sum of NAA and NAAG), total choline (tCho: the sum of GPC and PC), total creatine (tCr: the sum of Cr and PCr), and sum of Glu and Gln (Glx). To calculate the absolute metabolite concentrations, an unsuppressed water signal was used as a reference. Quantification estimates of 2HG were considered unreliable and were excluded when the Cramer-Rao lower bounds, returned as the percentage of standard deviation (%SD) by LCMoDel, was greater than 35%.

Sequencing for *IDH1* and *IDH2* was performed for four out of five cases with ample tissue for DNA analysis. DNA was extracted from fresh frozen tissue using the QIAamp Blood & Tissue Kit (Qiagen, Valencia, CA, USA) or using a formalin-fixed, paraffin-embedded (FFPE) tumor tissue using the QIAamp DNA FFPE Tissue Kit (Qiagen). PCR amplification was performed using the following primer sets: forward 5'-ACCAAGGATGCTGCAGAAGC-3' and reverse 5'-AGATGGACGCCTATTTGTAAGT-3' at codon 132 for the *IDH1* gene, and forward 5'-AGCCCATCATCTGCAAAAAC-3' and reverse 5'-CAGTGGATCCCCTCTCCAC-3' at codon 172 for the *IDH2* gene [3], which were different from those used in the original study [1].

For fluorescence in situ hybridization (FISH) for 1p/19q codeletion, formalin-fixed paraffin-embedded (FFPE) hematoxylin and eosin (HE)-stained tissue sections were examined to determine areas with high tumor cell density and a lack of necrosis and hemorrhage. Areas of interest on the HE-stained slides were transcribed to the reverse side of the unstained FFPE sections using a diamond-tipped marker. The FISH assay was performed on 4- μ m-thick sections, using ZytoLight SPEC 1p36/1q25 and ZytoLight SPEC 19q13/19p13 probes for locus-specific 1p and 19q analysis, respectively, following the manufacturers' instructions (ZytoVision, Bremerhaven, Germany). Additionally, 1p36 and 19q13 locus-specific red fluorescent probes were used as deletion targets and 1q25 and 19p13 green probes were used as internal controls. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI). FISH was performed on a Z-stacked two-dimensional image using a fluorescence microscope BZ-9000 (KEYENCE, Osaka, Japan). A minimum of 100 adjacent, non-overlapping interphase nuclei were examined for each assay. Whereas normal diploid

nuclei displayed a signal ratio of 2/2, a nucleus was considered to harbor a deletion if the target signal was 1 (i.e., 2/1) in relation to normal control signals. If the number of deleted nuclei was $\geq 50\%$, the tumor was considered to present a deletion of the targeted chromosome part [4].

3. Results

3.1. Rare *IDH2* Mutation Detected in a Recurrent “False-Positive” Case

In the original study, a 2HG of 1.489 mM or higher was detected in 5 of 27 (18.5%) gliomas that were determined to be *IDH*-wildtype. Recently, the tumor was found to have recurred in one of the five patients, and subsequently, the patient underwent a second surgery. A single voxel MRS, taken before the first surgery, showed characteristic small peaks at a chemical shift of approximately 2.25 ppm, reflecting 2HG (Figure 1A) and a high 2HG accumulation of 6.820 mM. A molecular analysis of the recurrent tumor via Sanger sequencing using a different *IDH2* primer revealed an *IDH2* R172W mutation (Figure 1B), and the pathological diagnosis was anaplastic oligodendroglioma, *IDH*-mutant and 1p/19q-codeleted. We re-analyzed the *IDH2* status in the tumor from the initial surgery and found an *IDH2* R172W mutation, albeit with a very small mutant peak (Figure 1C).




Figure 1. Rare *IDH2* mutation diagnosed at relapse. (A) Single voxel MRS (SVMRS) spectra showing small peaks (red arrows) at a chemical shift of approximately 2.25 ppm reflect the presence of 2-hydroxyglutarate (2HG). 2HG was quantified as 6.820 mM. (B) Obvious *IDH2* R172W mutation was detected at relapse. (C) Reassessment of *IDH2* mutation in the initial tumor revealed a small, mutant peak.

3.2. Re-Evaluation of IDH1 and IDH2 Mutations in Remaining Cases

Subsequently, we re-evaluated the *IDH1* and *IDH2* status in three out of the four remaining “false-positive” tumors with available tissue and found a *IDH2* R172K mutation in 1 patient with subtle peaks at a chemical shift of 2.25 ppm (Figure 2A). A very small mutant peak was detected using Sanger sequencing (Figure 2B). Morphologically, perinuclear halos, chicken-wire vessels and calcification were observed, all of which are characteristic of oligodendrogliomas (Figure 2C). Furthermore, 1p (Figure 2D) and 19q (Figure 2E) deletions were confirmed by fluorescence in situ hybridization. The tumor was diagnosed as an oligodendroglioma, IDH-mutant and 1p/19q-codeleted, according to WHO2016 [5].




Figure 2. *IDH2* mutation identified in a second case. (A) SVMRS spectra show minimal peaks at 2.25 ppm (red arrows) and 2HG quantified to be 2.763 mM. (B) A small, *IDH2* R172K-mutant peak was detected. (C) Morphologically, tumor cells with perinuclear halos lacking astrocytic processes, chicken-wire vessels and calcification were observed, suggestive of oligodendroglioma (scale bar = 20 μ m). Codeletion of 1p (D) and 19q (E) were detected by fluorescence in situ hybridization (FISH).

Thus, we found that the MRS was correct, and that we initially failed to detect rare *IDH2* mutations in two out of the five cases. The specificity of 2HG, at a cutoff of 1.489 mM to determine IDH mutation, was calculated to be 81.3%, not 72.2%, as originally reported [1]. The demographics of the five cases are summarized below (Table 1).

Table 1. Characteristics of the 5 presumed, false-positive cases.

Case No.	1	2	3	4	5
Age	30	51	59	72	67
Sex	F	F	M	F	F
Location	Rt Frontal	Rt Parietal	Rt Frontal	Rt Temporal	Lt Thalamus
2HG (mM)	6.820	2.763	5.589	4.477	5.448
Lactate (mM)	1.912	4.824	0.189	0.000	6.874
IDH1 R132H IHC	Negative	Negative	Negative	Negative	Negative
IDH 1/2 sequence	<i>IDH2</i> R172W	<i>IDH2</i> R172K	WT ⁶	WT ⁶	N/A ⁴
Mutant peak	Small	Small	None	None	N/A ⁴
1p/19q FISH	1p/19q codel ¹	1p/19q codel ¹	N/A ⁴	N/A ⁴	N/A ⁴
Pathological diagnosis	OD ⁵	OD ⁵	DA ²	GBM ³	DA ²

¹ codeleted; ² diffuse astrocytoma; ³ glioblastoma; ⁴ not available/not applicable; ⁵ oligodendroglioma; ⁶ wildtype.

We compared the metabolite concentrations of true-positive cases ($n = 2$) and false-positive cases ($n = 3$) (Table 2). Due to the small number of cases, the median concentration of metabolites between the two groups did not reach statistical significance. However interestingly, we found that the median GSH and Glu+Gln concentrations were lower, and the median Lac concentration was higher in the true-positive group than in the false-positive group, which is consistent with data that we [1,6] and others [7,8] have previously reported in IDH-mutant versus IDH-wildtype gliomas.

Table 2. Comparison of metabolites between true-positive and false-positive cases.

Metabolite	Median Concentration (mM) True-Positive Cases ($n = 2$)	Median Concentration (mM) False Positive Cases ($n = 3$)	<i>p</i> -Value
GSH ¹	1.020	1.839	0.40
2HG ²	4.792	5.448	>0.99
mI ³	5.561	3.862	0.40
Lac ⁴	4.393	0.189	0.40
tCh ⁵	1.563	1.860	0.80
tNAA ⁶	3.165	4.085	0.40
tCr ⁷	3.803	5.890	0.80
Glu+Gln ⁸	5.055	12.35	0.20

¹ glutathione; ² 2-hydroxyglutarate; ³ myoinositol; ⁴ lactate; ⁵ total choline; ⁶ total N-acetylaspartate; ⁷ total creatine;

⁸ glutamate + glutamine.

4. Discussion

In the present study, we re-evaluated five gliomas initially assessed to be of IDH wild-type but showed a high accumulation of 2HG and were thought to be false-positive. Two cases harbored rare *IDH2* R172 mutations that were not detected in the original analysis. The 2HG molecule contains five nonexchangeable protons, giving rise to multiplets at three locations on MRS: of approximately 4.02, 2.25, and 1.90 ppm [9]. The largest multiplet is located at 2.25 ppm. The detection of this multiplet is complicated by the spectral overlap of glutamate (Glu; 2.43 ppm), glutamine (Gln; 2.34 ppm), and gamma-aminobutyric acid (GABA; 2.28 ppm), all of which share the ⁴CH₂ group [10]. This can be expected given the structural similarities of Glu, Gln and 2HG. The direct detection of the multiplet at 1.90 ppm is made difficult due to its proximity to the NAA resonance at 2.01 ppm, which shares ³CH₂. Finally, the multiplet at 4.02 partially overlaps with creatine (Cr; 3.92 ppm), phosphocreatine (PCr; 3.94 ppm), myoinositol (Ins; 4.06 ppm), lactate (Lac; 4.1 ppm) and free

choline (fCh; 4.05 ppm), sharing $^2\text{CH}_2$ [9], which makes the unambiguous detection of 2HG challenging. A false-positive rate of approximately 22% was observed by Pope et al. using short-echo MRS (TE at 30 ms) for the detection of 2HG in gliomas [11]. This false-positive rate can be reduced by using long-echo MRS with TE at 97 ms and three-dimensional volume-localized basis (VLB) spectra, minimizing the effect of macromolecules in the detection of 2HG [9,12]. Other studies suggest that 2HG/[lipid + lactate] ratios [8] or a combination of 2HG and Glu [7] can provide a higher diagnostic accuracy than 2HG alone.

The sampling error must be considered when assessing the DNA of tumor tissues, especially when using frozen tissue. A recent study by Barritault et al. detected IDH1 and TERT promoter mutations from non-diagnostic biopsies from glioma patients using SNaPshot polymerase chain reaction [13], suggesting that methods that are more sensitive than Sanger sequencing may detect mutations in tissues with a low tumor volume. Since the mutant peak was small in both cases with detected *IDH2* mutation, we suspect that the tumor volume was low in these cases.

The limitations of this study include the small number of subjects, a suboptimal analysis of 2HG at a TE of 30 ms, the lack of ample tissue for DNA testing in one case, and an inability to detect rare IDH1/2 mutations differentiated from *IDH1* R132 and *IDH2* R172, such as *IDH1* R100Q. Thus, we were unable to determine the exact cause of the false-positive results in the remaining three cases.

One of the advantages of detecting 2HG by MRS is the non-invasive screening for rare mutations of *IDH1* and *IDH2*, as all IDH mutations are known to produce 2HG [14]. Highly reliable antibodies for IDH1 R132H, which constitutes approximately 90% of all IDH mutations in gliomas [3,15], are commercially available and widely used [16,17], but antibodies for other IDH1 and IDH2 mutant proteins are less widely available [18]. A recent, multicenter study suggested that non-IDH1-R132H IDH1/2 mutations are associated with an improved survival for astrocytomas compared to their R132H-mutant counterpart [19], which provides a basis for analyzing these rare mutations. In the present study, rare *IDH2* mutations were found in 2 out of 5 cases initially thought to be false-positive for 2HG. Both cases were pathologically diagnosed as oligodendrogliomas, which are known to almost uniformly harbor IDH mutations and 1p/19q codeletions [5].

Author Contributions: Conceptualization, M.N., H.I.; methodology, M.N., H.I., K.M., K.O.; formal analysis, M.N., H.I., K.M.; investigation, M.N., R.G., H.T., R.O., J.W., Y.T., K.O.; writing—original draft preparation, M.N.; writing—review and editing, H.I., R.G., K.O., A.K.; supervision, H.I., T.N., Y.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Ethical approval was obtained in accordance with the human research guidelines of the Institutional Review Board of Niigata University (Approval #2017-0163, approval date is 11 September 2017).

Informed Consent Statement: Written informed consent was obtained from all participants involved in the study.

Data Availability Statement: The datasets analyzed during the current study are available from the corresponding author upon request.

Acknowledgments: We would like to acknowledge all who helped with imaging, Ken Ohno for assistance in imaging analysis, Sumihito Nobusawa of Department of Human Pathology, Gunma University Graduate School of Medicine, for providing information about primers and Shingo Nigorikawa for technical assistance with molecular analyses.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Natsumeda, M.; Igarashi, H.; Nomura, T.; Ogura, R.; Tsukamoto, Y.; Kobayashi, T.; Aoki, H.; Okamoto, K.; Kakita, A.; Takahashi, H.; et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: A study by 3.0-tesla magnetic resonance spectroscopy. *Acta Neuropathol. Commun.* **2014**, *2*, 158. [[CrossRef](#)] [[PubMed](#)]
2. Provencher, S. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magn. Reson. Med.* **1993**, *30*, 672–679. [[CrossRef](#)] [[PubMed](#)]
3. Hartmann, C.; Meyer, J.; Balss, J.; Capper, D.; Mueller, W.; Christians, A.; Felsberg, J.; Wolter, M.; Mawrin, C.; Wick, W.; et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. *Acta Neuropathol.* **2009**, *118*, 469–474. [[CrossRef](#)] [[PubMed](#)]
4. Ambros, P.F.; Ambros, I.M. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. *Med. Pediatr. Oncol.* **2001**, *37*, 492–504. [[CrossRef](#)] [[PubMed](#)]
5. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Ellison, D.W.; Figarella-Branger, D.; Perry, A.; Reifenberger, G.; von Deimling, A. *WHO Classification of Tumours of the Central Nervous System*; IARC: Lyon, France, 2016.
6. Natsumeda, M.; Motohashi, K.; Igarashi, H.; Nozawa, T.; Abe, H.; Tsukamoto, Y.; Ogura, R.; Okada, M.; Kobayashi, T.; Aoki, H.; et al. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: A study by 3-T magnetic resonance spectroscopy. *Neurosurg. Rev.* **2018**, *41*, 641–647. [[CrossRef](#)] [[PubMed](#)]
7. Nagashima, H.; Tanaka, K.; Sasayama, T.; Irino, Y.; Sato, N.; Takeuchi, Y.; Kyotani, K.; Mukasa, A.; Mizukawa, K.; Sakata, J.; et al. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. *Neuro-Oncology* **2016**, *18*, 1559–1568. [[CrossRef](#)] [[PubMed](#)]
8. Suh, C.H.; Kim, H.S.; Park, J.E.; Jung, S.C.; Choi, C.G.; Woo, D.C.; Lee, H.B.; Kim, S.J. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas. *Radiol. Imaging Cancer* **2020**, *2*, e190083. [[CrossRef](#)] [[PubMed](#)]
9. Choi, C.; Ganji, S.; Hulsey, K.; Madan, A.; Kovacs, Z.; Dimitrov, I.; Zhang, S.; Pichumani, K.; Mendelsohn, D.; Mickey, B.; et al. A comparative study of short- and long-TE (1)H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. *NMR Biomed.* **2013**, *26*, 1242–1250. [[CrossRef](#)] [[PubMed](#)]
10. Govindaraju, V.Y.K.; Maudsley, A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. *NMR Biomed.* **2000**, *13*, 129–153. [[CrossRef](#)]
11. Pope, W.B.; Prins, R.M.; Albert Thomas, M.; Nagarajan, R.; Yen, K.E.; Bittinger, M.A.; Salamon, N.; Chou, A.P.; Yong, W.H.; Soto, H.; et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. *J. Neurooncol.* **2012**, *107*, 197–205. [[CrossRef](#)] [[PubMed](#)]
12. Choi, C.; Ganji, S.K.; DeBerardinis, R.J.; Hatanpaa, K.J.; Rakheja, D.; Kovacs, Z.; Yang, X.L.; Mashimo, T.; Raisanen, J.M.; Marin-Valencia, I.; et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat. Med.* **2012**, *18*, 624–629. [[CrossRef](#)] [[PubMed](#)]
13. Barritault, M.; Picart, T.; Poncet, D.; Fenouil, T.; d’Hombres, A.; Gabut, M.; Guyotat, J.; Jouanneau, E.; Ameli, R.; Joubert, B.; et al. Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies from Glioma Patients. *Neurosurgery* **2020**, *87*, E513–E519. [[CrossRef](#)] [[PubMed](#)]
14. Gross, S.; Cairns, R.A.; Minden, M.D.; Driggers, E.M.; Bittinger, M.A.; Jang, H.G.; Sasaki, M.; Jin, S.; Schenkein, D.P.; Su, S.M.; et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. *J. Exp. Med.* **2010**, *207*, 339–344. [[CrossRef](#)] [[PubMed](#)]
15. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH 1 and IDH 2 mutations in gliomas. *N. Engl. J. Med.* **2009**, *360*, 765–773. [[CrossRef](#)] [[PubMed](#)]
16. Capper, D.; Weissert, S.; Balss, J.; Habel, A.; Meyer, J.; Jager, D.; Ackermann, U.; Tessmer, C.; Korshunov, A.; Zentgraf, H.; et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathol.* **2010**, *20*, 245–254. [[CrossRef](#)] [[PubMed](#)]
17. Kato, Y.; Jin, G.; Kuan, C.T.; McLendon, R.E.; Yan, H.; Bigner, D.D. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. *Biochem. Biophys. Res. Commun.* **2009**, *390*, 547–551. [[CrossRef](#)] [[PubMed](#)]
18. Kato, Y. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. *Brain Tumor Pathol.* **2015**, *32*, 3–11. [[CrossRef](#)] [[PubMed](#)]
19. Tesileanu, C.M.S.; Vallentgoed, W.R.; Sanson, M.; Taal, W.; Clement, P.M.; Wick, W.; Brandes, A.A.; Baurain, J.F.; Chinot, O.L.; Wheeler, H.; et al. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. *Acta Neuropathol.* **2021**, *141*, 945–957. [[CrossRef](#)] [[PubMed](#)]